Actualización práctica sobre la palmitoiletanolamida (PEAum) oral en el manejo del dolor crónico. Revisión narrativa

Rafael Gálvez Mateos, Antonio Aguilar Ros
{"title":"Actualización práctica sobre la palmitoiletanolamida (PEAum) oral en el manejo del dolor crónico. Revisión narrativa","authors":"Rafael Gálvez Mateos, Antonio Aguilar Ros","doi":"10.20986/mpj.2023.1044/2023","DOIUrl":null,"url":null,"abstract":"Introduction: Chronic pain is a cause of great suffering for patients and their relatives and one of the most relevant health issues. Available treatments, generally based on analgesic drugs, mainly NSAIDs, and othres, including opioids, achieve a partial and frequently temporary relief, with a large number of potential adverse effects. Development: New investigation lines of research in this field are looking to develop safe analgesics like ultramicronised palmitoylethanolamide (um-PEA), a nutritional oral supplementation administered at a dose of 600mg/12-24 hours, to counteract neuroinflammation, slow down pain chronicity, enhancing the antinociceptive effects of analgesic drugs. Conclusions: PEAum is a nutritional support showing analgesic, anti-inflammatory and nerve regenerative properties, indicated for use in case of chronic pain, specially neuropathic pain. Um-PEA is able to decrease pain preventing, partially, central sensitisation. Um-PEA safety profile and good tolerability represent an additional tool in the management of chronic pain.","PeriodicalId":239479,"journal":{"name":"Multidisciplinary Pain Journal","volume":"55 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Multidisciplinary Pain Journal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.20986/mpj.2023.1044/2023","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Chronic pain is a cause of great suffering for patients and their relatives and one of the most relevant health issues. Available treatments, generally based on analgesic drugs, mainly NSAIDs, and othres, including opioids, achieve a partial and frequently temporary relief, with a large number of potential adverse effects. Development: New investigation lines of research in this field are looking to develop safe analgesics like ultramicronised palmitoylethanolamide (um-PEA), a nutritional oral supplementation administered at a dose of 600mg/12-24 hours, to counteract neuroinflammation, slow down pain chronicity, enhancing the antinociceptive effects of analgesic drugs. Conclusions: PEAum is a nutritional support showing analgesic, anti-inflammatory and nerve regenerative properties, indicated for use in case of chronic pain, specially neuropathic pain. Um-PEA is able to decrease pain preventing, partially, central sensitisation. Um-PEA safety profile and good tolerability represent an additional tool in the management of chronic pain.
口服棕榈酰乙醇酰胺(PEAum)在慢性疼痛管理中的实用更新。修订故事
慢性疼痛是患者及其亲属遭受巨大痛苦的原因,也是最相关的健康问题之一。现有的治疗方法,通常基于镇痛药物,主要是非甾体抗炎药和其他药物,包括阿片类药物,实现部分和经常是暂时的缓解,有大量潜在的不良反应。发展:该领域的新研究正在寻求开发安全的镇痛药,如超微化棕榈酰乙醇酰胺(um-PEA),这是一种营养口服补充剂,剂量为600mg/12-24小时,可对抗神经炎症,减缓疼痛的慢性,增强镇痛药物的抗伤害作用。结论:PEAum是一种具有镇痛、抗炎和神经再生功能的营养支持剂,适用于慢性疼痛,特别是神经性疼痛。Um-PEA能够减轻疼痛,部分预防中枢致敏。Um-PEA的安全性和良好的耐受性是治疗慢性疼痛的另一种工具。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信